Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000932471-25-000780·CytomX Therapeutics, Inc.
Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock · CUSIP: 23284F105
Event date: 2025-06-30
- Filing-level shares
- 9,379,794
- Percent of class
- 5.95%
- The Vanguard Group
Shares: 9,379,794 · Class: 5.95%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000780
- Form type
- SCHEDULE 13G/A
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- Jul 29, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership